As part of a program to synthesize the ceramide trisaccharide ( 1) related to Fabry's disease, methyl 4- O-(4- O-α- d -galactopyranosyl-β- d -galactopyranosyl)-β- d -glucopyranoside ( 12) was prepared. Methyl β-lactoside ( 2) was converted into methyl 4- O-(4,6- O-benzylidene-β- d -galactopyranosyl)-β- d -glucopyranoside ( 4). Methyl 2,3,6-tri- O-benzoyl-4- O-(2,3,6-tri- O-benzoyl-β- d -galactopyranosyl)-β- d -glucopyranoside ( 7) was synthesized from 4 through the intermediates methyl 2,3,6-tri- O-benzoyl-4- O-(4,6- O-benzylidene-2,3-di- O-benzoyl-β- d -galactopyranosyl)-β- d -glucopyranoside ( 5) and methyl 2,3,6-tri- O-benzoyl-4- O-(2,3-di- O-benzoyl-β- d -galactopyranosyl)-β- d -glucopyranoside ( 6). The halide-catalyzed condensation of 7 with 2,3,4,6-tetra- O-benzyl- d -galactopyranosyl bromide ( 8) gave methyl 2,3,6-tri- O-benzoyl-4- O-[2,3,6-tri- O-benzoyl-4- O-(2,3,4,6-tetra- O-benzyl-α- d -galactopyranosyl)- β- d -galactopyranosyl]-β- d -glucopyranoside ( 10). Stepwise deprotection of 10 led to 12, the methyl β-glycoside of the trisaccharide related to Fabry's disease.